Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis

TARRYTOWN, N.Y., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization... Biopharmaceuticals, Dermatology, Regulatory Regeneron Pharmaceuticals, Sanofi, DUPIXENT, dupilumab, atopic dermatitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news